| Literature DB >> 35625159 |
Germán David Mendoza-Martínez1, Pedro Abel Hernández-García2, Fernando Xicoténcatl Plata-Pérez1, José Antonio Martínez-García1, Augusto Cesar Lizarazo-Chaparro3, Ismael Martínez-Cortes1, Marcia Campillo-Navarro4, Héctor Aarón Lee-Rangel5, María Eugenia De la Torre-Hernández1,6, Adrian Gloria-Trujillo1.
Abstract
Choline chloride is used to provide choline in dog foods; however, in other domestic species, it has been replaced with a polyherbal containing phosphatidylcholine. A polyherbal containing Achyrantes aspera, Trachyspermum ammi, Citrullus colocynthis, Andrographis paniculata, and Azadirachta indica was evaluated in adult dogs through body weight changes, subcutaneous fat thickness, blood metabolites, and gene expression. Forty dogs (4.6 ± 1.6 years old) who were individually housed in concrete kennels were randomly assigned to the following treatments: unsupplemented diet (377 mg choline/kg), choline chloride (3850 mg/kg equivalent to 2000 mg choline/kg diet), and polyherbal (200, 400, and 800 mg/kg) for 60 days. Blood samples were collected on day 59 for biochemistry, biometry, and gene expression analysis through microarray assays. Intake, final body weight, and weight changes were similar for the two choline sources. Feed intake variation among dogs (p = 0.01) and dorsal fat (p = 0.03) showed a quadratic response to herbal choline. Dogs that received the polyherbal diet had reduced blood cholesterol levels (Quadratic, p = 0.02). The gene ontology analysis indicated that 15 biological processes were modified (p ≤ 0.05) with implications for preventing cardiovascular and metabolic diseases, cancer prevention, inflammatory and immune response, and behavior and cognitive process. According to these results that were observed in a 60 day trial, the polyherbal form could replace choline chloride in dog diets at a concentration of 400 mg/kg.Entities:
Keywords: Canis familiaris; feed plant additive; health; nutrigenomics
Year: 2022 PMID: 35625159 PMCID: PMC9137459 DOI: 10.3390/ani12101313
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Effect of polyherbal level versus choline chloride (mg/kg) on feed intake (FI), body weight (BW) changes, dorsal fat, and energy intake.
| Polyherbal | Choline Chloride Δ | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Item | 0 | 200 | 400 | 800 | 3850 | SEM | L | Q | K * |
| FI g/d | 239.4 | 235.5 | 236.2 | 229.4 | 238.9 | 20.51 | 0.75 | 0.95 | 0.82 |
| FI variation among dogs % | 10.00 | 10.40 | 7.14 | 18.28 | 9.10 | 2.13 | 0.02 | 0.01 | 0.25 |
| Initial BW kg | 10.70 | 10.24 | 10.28 | 10.06 | 10.56 | 1.297 | 0.85 | 0.70 | 0.68 |
| Final BW kg | 10.66 | 10.56 | 10.52 | 9.90 | 10.41 | 1.422 | 0.41 | 0.11 | 0.60 |
| ADG g/d | −0.52 | 6.25 | 3.95 | −2.81 | 0.93 | 6.175 | 0.62 | 0.20 | 0.85 |
| Dorsal fat mm | 2.77 | 3.14 | 3.22 | 2.86 | 2.64 | 0.283 | 0.66 | 0.03 | 0.05 |
| Energy expenditure Kcal/d | 900.4 | 862.4 | 873.0 | 847.7 | 893.9 | 85.59 | 0.70 | 0.94 | 0.69 |
* Contrast: Polyherbal vs. synthetic choline; SEM: Standard error of the mean; L: linear effect; Q: quadratic effect; FI: feed intake; ADG: average daily gain; Δ This is equivalent to 2000 mg/kg choline.
Effect of the polyherbal level and choline chloride (mg/kg) on the blood chemistry of dogs.
| Polyherbal | Choline Chloride Δ | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Item | 0 | 200 | 400 | 800 | 3850 | SEM | L | Q | K * |
| Glucose, mg/dL | 65.90 | 57.57 | 55.08 | 56.49 | 58.61 | 4.346 | 0.12 | 0.27 | 0.65 |
| Cholesterol, mg/dL | 192.31 | 144.92 | 160.11 | 175.68 | 145.08 | 13.201 | 0.56 | 0.02 | 0.32 |
| Urea, mg/dL | 32.99 | 23.96 | 53.69 | 28.72 | 32.89 | 11.89 | 0.60 | 0.41 | 0.98 |
| Uric acid, mg/dL | 0.289 | 0.302 | 0.450 | 0.343 | 0.238 | 0.077 | 0.37 | 0.44 | 0.16 |
| Creatinine, mg/dL | 0.662 | 0.674 | 0.724 | 0.663 | 0.737 | 0.056 | 0.83 | 0.51 | 0.45 |
| Total protein, g/dL | 6.50 | 6.17 | 6.32 | 6.39 | 6.06 | 0.246 | 0.88 | 0.42 | 0.41 |
| Albumin, g/dL | 3.36 | 3.24 | 3.21 | 3.14 | 3.26 | 0.116 | 0.19 | 0.81 | 0.63 |
| Globulin, g/dL | 3.08 | 2.88 | 3.11 | 3.24 | 2.68 | 0.193 | 0.42 | 0.39 | 0.08 |
| Bilirubin, mg/dL | 0.474 | 0.595 | 0.577 | 0.671 | 0.574 | 0.088 | 0.15 | 0.88 | 0.70 |
| ALP, UI/L | 56.37 | 43.00 | 54.16 | 44.94 | 44.88 | 10.723 | 0.63 | 0.84 | 0.84 |
| LDH, UI/L | 529.4 | 490.9 | 394.2 | 494.0 | 449.3 | 67.8 | 0.50 | 0.31 | 0.89 |
| AST, UI/L | 51.78 | 42.24 | 52.72 | 53.69 | 51.08 | 6.772 | 0.59 | 0.44 | 0.84 |
| Calcium, mg/dL | 8.68 | 8.23 | 7.77 | 8.05 | 8.38 | 0.348 | 0.13 | 0.30 | 0.37 |
| P, mg/dL | 4.24 | 3.75 | 4.32 | 4.42 | 4.21 | 0.396 | 0.53 | 0.47 | 0.92 |
* Contrast: polyherbal vs. choline chloride; AST: aspartate aminotransferase; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; P: phosphorus; SEM: Standard error of the mean; L: linear effect; Q: Quadratic effect. Δ This is equivalent to 2000 mg/kg choline.
Effect of the polyherbal level and choline chloride supplementation (mg/kg) on the blood count of dogs.
| Polyherbal | Choline Chloride Δ | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Item | 0 | 200 | 400 | 800 | 3850 | SEM | L | Q | K * |
| Hemoglobin, g/dL | 16.69 | 17.16 | 16.89 | 16.69 | 16.75 | 0.459 | 0.88 | 0.44 | 0.76 |
| Hematocrit, % | 49.76 | 50.98 | 51.38 | 50.29 | 50.37 | 1.572 | 0.78 | 0.46 | 0.78 |
| Erythrocytes, 106/mL | 7.45 | 7.75 | 7.46 | 7.37 | 7.53 | 0.267 | 0.66 | 0.46 | 0.98 |
| Leukocytes, 103/mL | 18.02 | 12.18 | 11.51 | 14.52 | 11.15 | 1.644 | 0.90 | 0.14 | 0.40 |
| Lymphocytes, % | 19.95 | 27.84 | 23.42 | 24.81 | 26.32 | 3.032 | 0.46 | 0.28 | 0.77 |
| Monocytes, % | 2.68 | 2.54 | 2.91 | 3.37 | 2.80 | 0.813 | 0.51 | 0.71 | 0.88 |
| Neutrophils, % | 74.08 | 64.49 | 70.88 | 68.58 | 69.30 | 3.270 | 0.49 | 0.27 | 0.72 |
| Eosinophils, % | 3.22 | 5.10 | 2.73 | 3.30 | 2.23 | 0.702 | 0.50 | 0.35 | 0.07 |
* Contrast: polyherbal vs. choline chloride; L: linear effect; Q: quadratic effect; SEM = standard error of the mean. Δ This is equivalent to 2000 mg/kg choline.
Biological processes enriched by polyherbal when compared to choline chloride Δ.
| Potential Implications in Dog 1 | Metabolic Pathway 2 | Fc 3 | |
|---|---|---|---|
| Prevention of cardiovascular and metabolic diseases | Renin–angiotensin system − | 3.4 | 0.03 |
| Carbohydrate absorption and digestion − | 3.3 | 0.02 | |
| PPAR signaling pathways − | 2.5 | 0.02 | |
| Prevention of cancer | Signaling pathways that regulate stem cell pluripotency (SPRSCP) − | 2.4 | 0.001 |
| TGFβ signaling pathways − | 2.2 | 0.03 | |
| Transcriptional dysregulation in cancer − | 2.3 | 0.002 | |
| Estrogen signaling pathways − | 2.2 | 0.03 | |
| Cholinergic synapse − | 2.1 | 0.03 | |
| FoxO signaling pathways − | 2.1 | 0.02 | |
| MAPK signaling pathways + | 2.0 | 0.01 | |
| Pathways in cancer − | 1.5 | 0.04 | |
| Inflammatory and immune response | Adherens junctions − | 2.5 | 0.03 |
| Cytokine–cytokine receptor interaction − | 1.7 | 0.02 | |
| Chemokine signaling pathways − | 1.7 | 0.04 | |
| Behavior and cognitive process | Addiction to nicotine − | 3.5 | 0.01 |
1 Authors classification; 2 analyses from DAVID 6.8 Bioinformatic gene set enrichment. 3 Fc: fold enrichment. PPAR: peroxisome proliferator associated receptor. TGFβ: transformer growth factor β. FoxO: forkhead box transcription factor. MAPK: mitogen-activated protein kinase. – Biological processes were enrichment with down-regulated genes. + Biological processes were enrichment with up-regulated genes. Δ This is equivalent to 2000 mg/kg choline.
Changes in gene expression in dogs fed the polyherbal vs. choline chloride in processes related to disease prevention and metabolism.
|
|
|
| Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) ( | −2.1 |
| Carboxypeptidase A3, mast cell ( | −1.6 |
| Cathepsin A ( | −2.0 |
| Chymase 1, mast cell ( | −2.0 |
| Neurolysin (metallopeptidase M3 family) ( | −1.6 |
| Renin 1 structural ( | −1.6 |
|
|
|
| Amylase 1, salivary ( | −1.7 |
| Calcium channel, voltage-dependent, L type, alpha 1D subunit ( | −1.6 |
| Glucose-6-phosphatase, catalytic ( | −1.7 |
| Glucose-6-phosphatase, catalytic, 2 ( | −1.7 |
| Solute carrier family 2 (facilitated glucose transporter), member 2 ( | −1.6 |
| Solute carrier family 37 (glucose-6-phosphate transporter), member 4 ( | −2.4 |
| Thymoma viral proto-oncogene 1 ( | −2.0 |
|
|
|
| Aquaporin 7 ( | −2.3 |
| Carnitine palmitoyltransferase 2 ( | −2.3 |
| Cytochrome P450, family 4, subfamily a, polypeptide 10 ( | −1.8 |
| Cytochrome P450, family 8, subfamily b, polypeptide 1 ( | −1.8 |
| Matrix metallopeptidase 1a (interstitial collagenase) ( | −1.7 |
| Matrix metallopeptidase 1b (interstitial collagenase) ( | −1.8 |
| Phospholipid transfer protein ( | −1.6 |
| Solute carrier family 27 (fatty acid transporter), member 2 ( | −1.7 |
| Solute carrier family 27 (fatty acid transporter), member 5 ( | −1.6 |
| Sterol carrier protein 2, liver ( | −1.7 |
| Fatty acid-binding protein 7, brain ( | 2.2 |
| Cytochrome P450, family 27, subfamily a, polypeptide 1 ( | 2.6 |
| Peroxisome proliferator-activated receptor alpha ( | 3.1 |
Fc: fold change.
Changes in gene expression of dogs fed with polyherbal vs. choline chloride in biological processes related to cancer.
| SPRSCP | TGFβ | Estrogen | FoxO | Cancer * | MAPK * | TDC | Cholinergic Synapse | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | Fc | Gene | Fc | Gene | Fc | Gene | Fc | Gene | Fc | Gene | Fc | Gene | Fc | Gene | Fc |
|
| −1.7 |
| −2.1 |
| −1.8 |
| −3.3 |
| −1.9 |
| 4.1 |
| −1.7 |
| −1.6 |
|
| −2.3 |
| −3.9 |
| −1.6 |
| −2.1 |
| −1.9 |
| 1.9 |
| −3.3 |
| −1.6 |
|
| −1.7 |
| −2.2 |
| −1.8 |
| −2.0 |
| −2.1 |
| 2.4 |
| −1.7 |
| −1.8 |
|
| −2.1 |
| −2.1 |
| −1.6 |
| −1.7 |
| −1.7 |
| 2.3 |
| −1.6 |
| −1.6 |
|
| −1.7 |
| −1.8 |
| −1.7 |
| −1.7 |
| −1.8 |
| 2.2 |
| −1.9 |
| −2.0 |
|
| −1.8 |
| −1.8 |
| −1.6 |
| −1.7 |
| −1.8 |
| 1.8 |
| −1.9 |
| −1.6 |
|
| −2.1 |
| −1.6 |
| −1.7 |
| −1.7 |
| −2.1 |
| 3.0 |
| −1.9 |
| −1.8 |
|
| −2.6 |
| −2.8 |
| −1.7 |
| −1.8 |
| −1.8 |
| 2.2 |
| −1.6 |
| −1.7 |
|
| −1.9 |
| −2.5 |
| −1.8 |
| −1.7 |
| −1.9 |
| 1.7 |
| −1.7 |
| −1.7 |
|
| −2.4 |
| −1.8 |
| −1.6 |
| −1.6 |
| −1.7 |
| 2.0 |
| −2.0 |
| −1.8 |
|
| −1.8 |
| −1.9 |
| −2.0 |
| −1.6 |
| −1.6 |
| 1.9 |
| −2.1 |
| −1.9 |
|
| −1.6 |
| −1.7 |
| −2.0 |
| −1.5 |
| 1.9 |
| −2.1 |
| −2.0 | ||
|
| −1.7 |
| −1.5 |
| −1.8 |
| −1.7 |
| 2.8 |
| −1.7 | ||||
|
| −2.0 |
| −1.7 |
| −1.9 |
| −2.2 |
| 1.6 |
| −2.3 | ||||
|
| −1.6 |
| −2.1 |
| −1.8 |
| 1.6 |
| −1.6 | ||||||
|
| −2.3 |
| −1.7 |
| 1.6 |
| −2.3 | ||||||||
|
| −1.9 |
| −1.8 |
| 2.1 |
| −1.9 | ||||||||
|
| −1.6 |
| −1.8 | ||||||||||||
|
| −1.7 |
| −1.9 | ||||||||||||
|
| −1.7 | ||||||||||||||
|
| −1.8 | ||||||||||||||
|
| −1.9 | ||||||||||||||
|
| −1.8 | ||||||||||||||
|
| −1.8 | ||||||||||||||
|
| −1.6 | ||||||||||||||
|
| −2.0 | ||||||||||||||
|
| −1.8 | ||||||||||||||
|
| −1.6 | ||||||||||||||
|
| −2.3 | ||||||||||||||
* Signaling pathways; Fc: fold change; SPRSCP: signaling pathways that regulate stem cell pluripotency; TGFβ: transforming growth factor β; Fox O: forkhead box O; MAPK: Mitogen-activated protein kinase: TDC: Transcriptional dysregulation in cancer.
Changes in the gene expression of dogs fed with the polyherbal vs. choline chloride in the inflammatory process and immune response.
| Adherens Junctions | Chemokine Signaling Pathways | Cytokine–Cytokine Receptor Interaction | |||
|---|---|---|---|---|---|
| Gene | Fc | Gene | Fc | Gene | Fc |
|
| −1.6 |
| −2.1 |
| −2.2 |
|
| −2.1 |
| −1.9 |
| −2.1 |
|
| −2.0 |
| −1.8 |
| −2.2 |
|
| −2.4 |
| −2.2 |
| −1.6 |
|
| −1.9 |
| −1.6 |
| −1.6 |
|
| −1.7 |
| −1.6 |
| −1.9 |
|
| −2.2 |
| −1.9 |
| −1.8 |
|
| −1.7 |
| −1.8 |
| −2.4 |
|
| −1.8 |
| −2.4 |
| −1.7 |
|
| −1.7 |
| −1.7 | ||
|
| −1.7 |
| −1.5 | ||
|
| −1.7 |
| −1.7 | ||
|
| −1.7 |
| −1.8 | ||
|
| −2.0 |
| −1.6 | ||
|
| −1.6 |
| −2.8 | ||
|
| −1.6 |
| −2.1 | ||
|
| −2.0 |
| −2.0 | ||
|
| −1.8 | ||||
|
| −2.2 | ||||
|
| −1.6 | ||||
|
| −2.5 | ||||
Fc: Fold change.
Changes in gene expression in dogs fed with polyherbal vs. choline chloride in nicotine addiction processes.
| Gene | Fc |
|---|---|
| Cholinergic receptor, nicotinic, alpha polypeptide 7 ( | −1.8 |
| GABA A receptor, subunit alpha 1 ( | −2.3 |
| GABA A receptor, subunit alpha 4 ( | −1.8 |
| GABA A receptor, subunit beta 2 ( | −1.8 |
| GABA A receptor, subunit theta ( | −2.0 |
| Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter) ( | −2.3 |
| Solute carrier family 32 (GABA vesicular transporter), member 1( | −2.4 |
Fc: fold change; GABA: Gamma-aminobutyric acid.